What you own
Your slice of every Agronomics holding, at Agronomics' own valuations.
Market value
£4,800
at 4.80p · 30 Sep 2026
Share of NAV
Per £1
£2.68
62% below NAV
Cash
£115
0.11p a share
Holdings
- Within the share price
- Beyond it
- Price 4.80p
Liberation Bioindustries and SuperMeat alone: 5.04p a share, above the 4.80p price.
| Holding | Yours | Per share | Cost | Stage |
|---|---|---|---|---|
| Liberation Bioindustries | £3,257 | 3.26p | £2,021 | Pre-launch / scale-up (step 4 of 6) |
| SuperMeat | £1,782 | 1.78p | £1,403 | Pilot (step 2 of 6) |
| BlueNalu | £1,083 | 1.08p | £1,018 | Regulatory review (step 3 of 6) |
| Onego Bio | £1,029 | 1.03p | £656 | Pre-launch / scale-up (step 4 of 6) |
| Formo | £873 | 0.87p | £349 | Early commercial (step 5 of 6) |
| All G | £872 | 0.87p | £962 | Early commercial (step 5 of 6) |
| Clean Food Group | £645 | 0.64p | £148 | Early commercial (step 5 of 6) |
| The EVERY Company | £557 | 0.56p | £549 | Commercial (step 6 of 6) |
| Solar Foods | £552 | 0.55p | £487 | Early commercial (step 5 of 6) |
| LIVEKINDLY Collective | £386 | 0.39p | £215 | Commercial (step 6 of 6) |
| California Cultured | £322 | 0.32p | £149 | Regulatory review (step 3 of 6) |
| Meatly | £293 | 0.29p | £106 | Early commercial (step 5 of 6) |
| Mosa Meat | £291 | 0.29p | £287 | Regulatory review (step 3 of 6) |
| GALY | £230 | 0.23p | £103 | Early commercial (step 5 of 6) |
| Tropic | £209 | 0.21p | £212 | Early commercial (step 5 of 6) |
| CellX | £176 | 0.18p | £152 | Early commercial (step 5 of 6) |
| HydGene Renewables | £120 | 0.12p | £123 | Pilot (step 2 of 6) |
| Umami Bioworks | £34 | 0.03p | £37 | Pre-launch / scale-up (step 4 of 6) |
| Rebellyous Foods | £31 | 0.03p | £26 | Commercial (step 6 of 6) |
| Geltor | £22 | 0.02p | £666 | Commercial (step 6 of 6) |
| Good Protein Fund | £15 | 0.01p | £10 | |
| Laverock Therapeutics | £4 | <0.01p | £4 | R&D (step 1 of 6) |
| Legacy investments | £1 | <0.01p | — | |
| Since 30 Jun 2026 | −£15 | −0.01p | — | |
| Cash | £115 | 0.11p | — | |
| Receivables less payables | −£7 | −0.01p | — | |
| Your share of NAV | £12,878 | 12.88p | £9,682 |
Your slice = your shares ÷ 1,083,381,111 in issue. Company values at 30 Jun 2026 (Q2 2026 Investor Report); NAV, cash and shares at 30 Sep 2026 (Net Asset Value as at 30 September 2026). Share price at 30 Sep 2026.
What it's in
| Revenue | Share of holdings | Yours |
|---|---|---|
| Revenue | £996 | |
| Early revenue | £3,851 | |
| Pre-revenue | £7,922 | |
| Funds & legacy | £16 |
| Stage | Share of holdings | Yours |
|---|---|---|
| Commercial (step 6 of 6) | £996 | |
| Early commercial (step 5 of 6) | £3,851 | |
| Pre-launch / scale-up (step 4 of 6) | £4,319 | |
| Regulatory review (step 3 of 6) | £1,696 | |
| Pilot (step 2 of 6) | £1,903 | |
| R&D (step 1 of 6) | £4 | |
| Funds & legacy | £16 |
| Sector | Share of holdings | Yours |
|---|---|---|
| Cultivated meat & seafood | £3,483 | |
| Precision fermentation | £3,353 | |
| Fermentation infrastructure | £3,257 | |
| Biomass fermentation | £1,373 | |
| Plant cell culture | £552 | |
| Plant-based | £417 | |
| Gene editing & crops | £209 | |
| Other biotech | £125 | |
| Funds & legacy | £16 |
| Country | Share of holdings | Yours |
|---|---|---|
| United States | £5,678 | |
| Israel | £1,782 | |
| Finland | £1,581 | |
| United Kingdom | £1,151 | |
| Australia | £993 | |
| Germany | £873 | |
| Switzerland | £386 | |
| Netherlands | £291 | |
| Singapore | £34 | |
| Funds & legacy | £16 |